[ad_1]
Hemispherx Biopharma Inc. (NYSEAMERICAN: HEB), CEO of Tom Equels, told Proactive Investors that the company was excited about starting its Phase 1 studies using Ampligen as a combination drug therapy. Merck's Keytruda Cancer at Roswell Park Comprehensive Cancer Center in New York.
The study will establish the safety of therapies for treating advanced bad cancer. Equels expects safety and efficacy indicators six to nine months after full enrollment in the study.
Source link
